ImmunosenescenceNCT06907329
The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.
A study testing NMN in people with Immunosenescence and Overweight, run by Qing Su at 1 site in China.
Trial summary
This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. Read more about this study
- Who is it for?
- Ages 50 to 70 years
- Conditions the study is for
- Immunosenescence, Overweight, Obesity
- What is being tested?
- NMN
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 124 participants
- Where
- 1 siteChina
- Study dates
- 5 Jun 2025to 18 Oct 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- (1) Age 50-70 years with overweight or obesity (BMI ≥ 24 kg/m²);
- (2) At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c <7% without glucose-lowering drug therapy;
- (3) Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
Who cannot join
- (1) Patients with tumours;
- (2) Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
- (3) Severe cardiovascular disease or cardiac insufficiency;
- (4) Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg;
- (5) Chronic obstructive pulmonary disease;
- (6) Chronic active hepatitis or cirrhosis;
Show all 15Show fewer
- (7) Chronic renal insufficiency;
- (8) Stroke patients;
- (9) Severe haematological diseases;
- (10) Infectious diseases;
- (11) Mental illness;
- (12) Other conditions that, in the opinion of the investigator, may affect the results of the study;
- (13) Those who have used NMN or other anti-aging agents within six months;
- (14) Premenopausal women;
- (15) ALT, AST values are more than three times higher than the upper limit of the normal reference range;
Trial locations and contacts
1 site in 1 country.
China1 site
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai
About this study
This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.
Read the detailed description
This single-center, randomized, placebo-controlled, parallel-group study evaluates the effects of nicotinamide mononucleotide (NMN) sustained-release tablets on immunosenescence and metabolism in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. A total of 124 participants were enrolled. Participants were randomly assigned to receive NMN sustained-release tablets (1,000 mg per tablet) or matching placebo, one tablet daily before breakfast for 26 weeks. Study visits were scheduled at months 1, 3, and 6.
The primary outcome is the change from baseline to Week 26 in the percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood, measured by flow cytometry. The change is calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Secondary assessments include other T-cell phenotypes, the CD8/CD4 ratio expressed as a percentage, hepatic steatosis, glucose metabolism, pancreatic beta-cell function, insulin resistance, body composition, anthropometric measures, whole-blood NMN and NAD+ concentrations, relative telomere length, and cardiorespiratory fitness. Hepatic steatosis is assessed using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and the controlled attenuation parameter (CAP) measured by FibroScan. Body composition outcomes, assessed by dual-energy X-ray absorptiometry (DXA), are total body fat mass, total body tissue fat percentage, total body lean mass, estimated visceral adipose tissue mass, and relative skeletal muscle index. Cardiorespiratory fitness outcomes, assessed by cardiopulmonary exercise testing, are peak oxygen uptake and oxygen uptake at the anaerobic threshold. Each secondary outcome is assessed as the change from baseline to Week 26 and analyzed separately.
Safety assessments include routine blood and urine tests and liver and kidney function tests.
- Conditions
- Immunosenescence, Overweight, Obesity, Metabolic Dysfunction-Associated Fatty Liver Disease, Prediabetic State, Diabetes Mellitus, Type 2
- Being tested
- NMN, Placebo
- Keywords
- Nicotinamide mononucleotide, NMN, NAD+, T-cell senescence, CD28, Aging
- Medical subject headings
- Overweight, Obesity, Prediabetic State, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NMNDietary supplement
Nicotinamide mononucleotide (NMN) sustained-release tablets, 1,000 mg per tablet, administered orally as one tablet once daily before breakfast for 26 weeks.
PlaceboDietary supplement
Matching placebo tablets, administered orally as one tablet once daily before breakfast for 26 weeks.
| Study group | Role | What they receive |
|---|---|---|
| NMN Arm | Experimental | Participants assigned to the NMN arm receive one sustained-release tablet containing 1,000 mg of nicotinamide mononucleotide orally once daily before breakfast for 26 weeks. Receives: Dietary Supplement: NMN |
| Placebo Arm | Placebo comparator | Participants assigned to the placebo arm receive one matching placebo tablet orally once daily before breakfast for 26 weeks. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Secondary outcomes (29)
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD27- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD28- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27- T Cells Among Total CD3+CD4+ T Cells
The percentage of CD3+CD4+CD27- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD28- T Cells Among Total CD3+CD4+ T Cells
The percentage of CD3+CD4+CD28- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27-CD28- T Cells Among Total CD3+CD4+ T Cells
The percentage of CD3+CD4+CD27-CD28- T cells among total CD3+CD4+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD45RA+CCR7- T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD45RA+CCR7- T cells (TEMRA cells) among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD57+KLRG1+ T Cells Among Total CD3+CD8+ T Cells
The percentage of CD3+CD8+CD57+KLRG1+ T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in the CD3+CD8+ to CD3+CD4+ T-Cell Ratio Expressed as a Percentage
CD3+CD8+ and CD3+CD4+ T cells in peripheral blood will be quantified by flow cytometry. The CD8/CD4 ratio will be expressed as a percentage by dividing the number of CD3+CD8+ T cells by the number of CD3+CD4+ T cells and multiplying by 100. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Liver Fat Content Assessed by MRI-PDFF
Liver fat content will be assessed by magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and expressed as a percentage. Change from baseline will be calculated as the Week 26 MRI-PDFF percentage minus the baseline MRI-PDFF percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Controlled Attenuation Parameter (CAP)
Hepatic steatosis will be assessed using the controlled attenuation parameter (CAP) measured by FibroScan and expressed in dB/m. Change from baseline will be calculated as the Week 26 CAP value minus the baseline CAP value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Fasting Blood Glucose
Fasting blood glucose will be measured in venous blood and expressed in mmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in 2-Hour Blood Glucose During an Oral Glucose Tolerance Test
Blood glucose at 2 hours during an oral glucose tolerance test (OGTT) will be measured in venous blood and expressed in mmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Glycated Hemoglobin (HbA1c)
Glycated hemoglobin (HbA1c) will be measured in whole blood and expressed as a percentage (%) of total hemoglobin. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in HOMA-beta
Pancreatic beta-cell function will be assessed using the homeostasis model assessment of beta-cell function (HOMA-beta), calculated from fasting glucose and fasting insulin and reported as an index. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in HOMA-IR
Insulin resistance will be assessed using the homeostasis model assessment of insulin resistance (HOMA-IR), calculated from fasting glucose and fasting insulin and reported as a unitless index. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Fat Mass Assessed by DXA
Total body fat mass will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Tissue Fat Percentage Assessed by DXA
Total body tissue fat percentage (fat mass as a percentage of total tissue mass) will be measured by whole-body dual-energy X-ray absorptiometry (DXA). Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Lean Mass Assessed by DXA
Total body lean mass will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Estimated Visceral Adipose Tissue Mass Assessed by DXA
Visceral adipose tissue mass will be estimated by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in g. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Relative Skeletal Muscle Index (RSMI) Assessed by DXA
Relative skeletal muscle index (RSMI), calculated as appendicular lean mass divided by height squared, will be measured by whole-body dual-energy X-ray absorptiometry (DXA) and expressed in kg/m^2. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Body Weight
Body weight will be measured using a weighing scale and expressed in kilograms. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Waist Circumference
Waist circumference will be measured using a tape measure and expressed in centimeters. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Waist-to-Hip Ratio
Waist and hip circumferences will be measured using a standardized tape measure following WHO measurement protocols. The waist-to-hip ratio will be calculated by dividing waist circumference by hip circumference, using the same units for both measurements. The ratio is unitless. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Waist-to-Height Ratio
Waist circumference and height will be measured following WHO measurement protocols. The waist-to-height ratio will be calculated by dividing waist circumference by height, using the same units for both measurements. The ratio is unitless. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Whole-Blood Nicotinamide Mononucleotide (NMN) Concentration
Nicotinamide mononucleotide (NMN) concentration will be measured in whole blood and expressed in nmol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Whole-Blood Nicotinamide Adenine Dinucleotide (NAD+) Concentration
The concentration of oxidized nicotinamide adenine dinucleotide (NAD+) will be measured in whole blood and expressed in micromol/L. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Relative Telomere Length in Peripheral Blood Cells
Relative telomere length in peripheral blood cells will be measured by quantitative real-time polymerase chain reaction (qPCR) and reported as a unitless value. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Peak Oxygen Uptake (Peak VO2)
Peak oxygen uptake will be measured during cardiopulmonary exercise testing and expressed in mL/min. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Change From Baseline to Week 26 in Oxygen Uptake at the Anaerobic Threshold (VO2-AT)
Oxygen uptake at the anaerobic threshold will be measured during cardiopulmonary exercise testing and expressed in mL/min. Change from baseline will be calculated as the Week 26 value minus the baseline value.
Measured: Baseline and Week 26
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2025
- Study start5 Jun 2025
- Primary completion18 Oct 2026
- Study completion18 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ImmunosenescenceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 124 participants (actual)
Sponsor and investigators
- Lead sponsor
- Qing Su
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Qing Su, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06907329
- Sponsor's protocol ID
- XHEC-C-2024-165-4
- Status last verified
- Oct 2026
- First submitted
- 19 Mar 2025
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.
- ClinicalTrials.gov ID
- NCT06907329
- Acronym / sponsor ID
- XHEC-C-2024-165-4
- Conditions
- Immunosenescence, Overweight, Obesity, Metabolic Dysfunction-Associated Fatty Liver Disease, Prediabetic State, Diabetes Mellitus, Type 2
- Keywords
- Nicotinamide mononucleotide, NMN, NAD+, T-cell senescence, CD28, Aging
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 124 participants (actual)
- Lead sponsor
- Qing SuUniversity, hospital or other
- Study start
- 5 Jun 2025 (actual)
- Primary completion
- 18 Oct 2026 (actual)
- Study completion
- 18 Oct 2026 (actual)
- First posted
- 2 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.
Detailed description
This single-center, randomized, placebo-controlled, parallel-group study evaluates the effects of nicotinamide mononucleotide (NMN) sustained-release tablets on immunosenescence and metabolism in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. A total of 124 participants were enrolled. Participants were randomly assigned to receive NMN sustained-release tablets (1,000 mg per tablet) or matching placebo, one tablet daily before breakfast for 26 weeks. Study visits were scheduled at months 1, 3, and 6.
The primary outcome is the change from baseline to Week 26 in the percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood, measured by flow cytometry. The change is calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
Secondary assessments include other T-cell phenotypes, the CD8/CD4 ratio expressed as a percentage, hepatic steatosis, glucose metabolism, pancreatic beta-cell function, insulin resistance, body composition, anthropometric measures, whole-blood NMN and NAD+ concentrations, relative telomere length, and cardiorespiratory fitness. Hepatic steatosis is assessed using magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) and the controlled attenuation parameter (CAP) measured by FibroScan. Body composition outcomes, assessed by dual-energy X-ray absorptiometry (DXA), are total body fat mass, total body tissue fat percentage, total body lean mass, estimated visceral adipose tissue mass, and relative skeletal muscle index. Cardiorespiratory fitness outcomes, assessed by cardiopulmonary exercise testing, are peak oxygen uptake and oxygen uptake at the anaerobic threshold. Each secondary outcome is assessed as the change from baseline to Week 26 and analyzed separately.
Safety assessments include routine blood and urine tests and liver and kidney function tests.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| NMN Arm | Experimental | Dietary Supplement: NMNParticipants assigned to the NMN arm receive one sustained-release tablet containing 1,000 mg of nicotinamide mononucleotide orally once daily before breakfast for 26 weeks. |
| Placebo Arm | Placebo comparator | Dietary Supplement: PlaceboParticipants assigned to the placebo arm receive one matching placebo tablet orally once daily before breakfast for 26 weeks. |
Who may qualify
- Ages
- 50 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- (1) Age 50-70 years with overweight or obesity (BMI ≥ 24 kg/m²);
- (2) At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c <7% without glucose-lowering drug therapy;
- (3) Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.
Key exclusion criteria (15 listed)
- (1) Patients with tumours;
- (2) Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
- (3) Severe cardiovascular disease or cardiac insufficiency;
- (4) Systolic blood pressure > 160 mmHg or diastolic blood pressure > 100 mmHg;
- (5) Chronic obstructive pulmonary disease;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NMNNicotinamide mononucleotide (NMN) sustained-release tablets, 1,000 mg per tablet, administered orally as one tablet once daily before breakfast for 26 weeks. | Dietary supplement | NMN Arm |
| PlaceboMatching placebo tablets, administered orally as one tablet once daily before breakfast for 26 weeks. | Dietary supplement | Placebo Arm |
Primary outcome
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T Cells Among Total CD3+CD8+ T Cells
Time frame: Baseline and Week 26
The percentage of CD3+CD8+CD27-CD28- T cells among total CD3+CD8+ T cells in peripheral blood will be measured by flow cytometry. Change from baseline will be calculated as the Week 26 percentage minus the baseline percentage and expressed in percentage points.
29 secondary outcomes
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27- T Cells Among Total CD3+CD8+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD28- T Cells Among Total CD3+CD8+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27- T Cells Among Total CD3+CD4+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD28- T Cells Among Total CD3+CD4+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD4+CD27-CD28- T Cells Among Total CD3+CD4+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD45RA+CCR7- T Cells Among Total CD3+CD8+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD57+KLRG1+ T Cells Among Total CD3+CD8+ T Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in the CD3+CD8+ to CD3+CD4+ T-Cell Ratio Expressed as a Percentage
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Liver Fat Content Assessed by MRI-PDFF
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Controlled Attenuation Parameter (CAP)
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Fasting Blood Glucose
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in 2-Hour Blood Glucose During an Oral Glucose Tolerance Test
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Glycated Hemoglobin (HbA1c)
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in HOMA-beta
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in HOMA-IR
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Fat Mass Assessed by DXA
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Tissue Fat Percentage Assessed by DXA
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Total Body Lean Mass Assessed by DXA
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Estimated Visceral Adipose Tissue Mass Assessed by DXA
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Relative Skeletal Muscle Index (RSMI) Assessed by DXA
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Body Weight
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Waist Circumference
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Waist-to-Hip Ratio
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Waist-to-Height Ratio
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Whole-Blood Nicotinamide Mononucleotide (NMN) Concentration
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Whole-Blood Nicotinamide Adenine Dinucleotide (NAD+) Concentration
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Relative Telomere Length in Peripheral Blood Cells
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Peak Oxygen Uptake (Peak VO2)
Time frame: Baseline and Week 26
Change From Baseline to Week 26 in Oxygen Uptake at the Anaerobic Threshold (VO2-AT)
Time frame: Baseline and Week 26
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Immunosenescence
RecruitingPhase 1/2
Precision Microbiota Interventions for Senoreduction Trial
HIV Infections, Alcohol Drinking
Not yet recruitingObservational study
Immune Aging and Advanced Therapy Outcomes in Older Adults With IBD
Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), Frailty
Recruiting
Can Exercise Ameliorate Immunosenescence and Thereby Reduce Relapse in Head and Neck Cancer Patients
Aging, High-intensity Interval Training
RecruitingPhase 4
Influenza Vaccine Immunogenicity in Repeatedly Vaccinated Older Adults
Influenza Vaccination, Older Adults (65 Years and Older)
RecruitingObservational study
Exploratory Study on Infection and Immunosenescence Based on an Elderly Clinical Cohort
Immunosenescence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NMN in people with Immunosenescence and Overweight, run by Qing Su at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline to Week 26 in the Percentage of CD3+CD8+CD27-CD28- T Cells Among Total CD3+CD8+ T Cells (time frame: Baseline and Week 26). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.